Status:

COMPLETED

Effect of Estradiol Pretreatment on Antagonist ICSI Cycles

Lead Sponsor:

Alexandria University

Conditions:

Female Infertility

Eligibility:

FEMALE

20-37 years

Phase:

PHASE4

Brief Summary

Depended on the hypothesis that growth asynchrony of antral follicles is a consequence of the gradual follicle stimulating hormone (FSH) elevation that occurs during the late luteal phase, the aim of ...

Detailed Description

Gonadotropin-releasing hormone antagonist (GnRH-ant) cycles are characterized by higher patient acceptability with more attention being directed to the potential effect of steroid pretreatment to prog...

Eligibility Criteria

Inclusion

  • Women age 20-37 years.
  • Anti-mullerian (AMH) level greater than 1.2 ng/ml.
  • Body mass index between 18 and 29 kg/m2.
  • Undergoing a first or second ICSI cycles.

Exclusion

  • Endometriosis.
  • Uterine disorders such as fibroids and uterine anomalies.
  • Antral follicular counts (AFC) less than 10.
  • Azoospermic males.

Key Trial Info

Start Date :

June 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 15 2021

Estimated Enrollment :

114 Patients enrolled

Trial Details

Trial ID

NCT05197374

Start Date

June 1 2020

End Date

November 15 2021

Last Update

February 3 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

IVF center

Alexandria, Egypt

Effect of Estradiol Pretreatment on Antagonist ICSI Cycles | DecenTrialz